Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare
Institute of Gastroenterology and Hepatology, Vietnam
380 participants
Aug 18, 2025
INTERVENTIONAL
Conditions
Summary
Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes. The GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians. The investigators are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.
Eligibility
Inclusion Criteria3
- ≥18 years old
- Presents with typical GERD symptoms (regurgitation, heartburn)
- Owns a smartphone and capable of using smartphone applications.
Exclusion Criteria4
- Acute GI conditions (upper GI bleeding, acute peptic ulcer…)
- GI malignancy (esophageal cancer, gastric cancer…)
- Severe chronic comorbidities (heart failure, liver failure, chronic kidney disease…)
- Pregnancy, alcohol abuse, mental health conditions impacting medication adherence or app usage
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Using the smartphone application GERDCare (with detailed instructions provided during recruitment)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07125521